scientific-drug-repurposing

Drug repurposing candidates are identified by integrating Open Targets, ChEMBL, and DrugBank data to apply target-based, network-based, and mechanism-based analyses. This process yields a structured top-10 candidate list with supporting evidence synthesis.

Multi-strategy drug repurposing systematically identifies new therapeutic uses for approved drugs across seven approaches, including phenotype-based and structure-based methods. It is needed to accelerate discovery by integrating pathways, network analyses, and literature evidence.

To generate a ranked repurposing report, apply multi-criteria scoring, safety profiling, and patent checks to the integrated evidence. This automated process prioritizes candidates and outputs comprehensive documentation with supporting literature.

Yes, the drug repurposing workflow supports network-based analysis alongside target-based and disease-driven strategies across multiple diseases. It integrates comprehensive evidence to generate actionable candidate lists for various therapeutic areas.

The best way to prioritize repurposing candidates is using automated multi-criteria scoring and evidence synthesis across seven strategies. This approach integrates DrugBank data to produce a top-10 candidate list with comprehensive supporting documentation.

Yes, you can run mechanism-based and phenotype-based drug repurposing analyses together within the same workflow. The system spans seven distinct strategies, automatically scoring and synthesizing evidence to output a unified top-10 candidate list.